Pfizer cans early-stage trials for cancer, sickle cell targets

Pfizer building
Pfizer HQ (Tracy Staton)

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

A few years back, Pfizer pretty much canned its entire neuro pipeline, but today the ax isn’t quite so red with blood. There’s a load of trials with its Merck-partnered Bavencio cancer drug that have been felled, but just two experimental trials: PF-06688992 in phase 1 for cancer and PF-04447943, also in phase 1 but for sickle cell anemia.

According to ClinicalTrials.gov, the former had been in an open-label trial for a small group of late-stage melanoma patients, completing two weeks ago. Trial data have not been shared.  

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

PF-06688992 works as an antibody-drug conjugate, a method of attack that has seen a mixture of success and failures in recent years, and is composed of a monoclonal antibody against the ganglioside GD3.

The therapy works by connecting to GD3, which is found on most melanomas but on very few other cells in the body, and the hope is that it will deliver the chemotherapy agent directly to the melanoma and not to normal cells, making it more targeted and less likely to produce side effects.

PF-04447943, meanwhile, works as a phosphodiesterase 9A inhibitor; a year ago, Pfizer dropped early data showing safety and early signs of possible efficacy, including a drop in biomarkers linked to vaso-occlusion.

The drug is aimed at sickle cell disease, caused by an inherited alteration in a gene that instructs the making of the beta-globin subunit of hemoglobin, the protein responsible for carrying oxygen in the blood, leading to sickle hemoglobin production and sickle-shaped red blood cells.

As ever, no details have been given about why these have been canned, with the trials simply listed under Pfizer's "discontinued projects" header in its updated pipeline.

Suggested Articles

Since Genentech scored a speedy review of its spinal muscular atrophy drug, the company has submitted more data, leading the FDA to extend its review.

Designed by OraSure, the test would detect the novel infection behind COVID-19 as well as all coronaviruses that can lead to respiratory disease.

President Donald Trump has asked “leading” pharma companies working on COVID-19 treatments to offer help to U.K. Prime Minister Boris Johnson.